Reducing the standard duration of home intravenous antibiotics for an infective exacerbation of bronchiectasis

Dr Rachel Scott and Dr Maria Miles
Supervised by Dr Mahableshwar Albur



What?

- NICE guidance¹ recommends 7-14 day abx course for exacerbations of bronchiectasis.
- 14 days is North Bristol NHS Trust current standard of practice
- Much of this is provided using IV abx at home via H@H

Aim: Reduce standard prescription for IV antibiotics from 14 to 10 days

Why?

- To reduce workload & wait times for H@H
- To reduce patient morbidity
 - Feasibility RCT study of 90 pts showed 7-10days of abx reduces time to next exacerbation (compared with 14 days)¹. Larger NIHR-funded RCT ongoing²
- To improve antimicrobial stewardship
- To reduce burden on patients and improve regimen adherence

¹⁾ Bedi, P., Cartlidge, M.K., Zhang, Y., Turnbull, K., Donaldson, S., Clarke, A., Crowe, J., Campbell, K., Graham, C., Franguylan, R. and Rossi, A.G., 2021. Feasibility of shortening intravenous antibiotic therapy for bronchiectasis based on bacterial load: a proof-of-concept randomised controlled trial. European Respiratory Journal, 58(6).

How?

Aim: Reduce standard prescription for IV antibiotics from 14 to 10 days

- Call from respiratory consultant at 9 days, if inadequate clinical improvement extend to 14 days

Primary outcome measure:


Total duration of course of IV antibiotics for an infective exacerbation of bronchiectasis

Balancing measures:

- Failure of treatment (admission to hospital, extended or repeated course of abx or death within one month)

Process measures:


- Sputum cultures prior to and following abx course
- Delay to commencing IV abx with H@H (days from referral to commencement of abx)




Results: abx duration

	Baseline		Cycle 1		Cycle 2		
	June - Sept		Oct - Dec		Jan - April		p value
Referrals to OPAT	n	%	n	%	n	%	
Number of patients	16		19		21		
Ward referral	5	31%	5	26%	3	14%	0.445
Outpatient	11	69%	14	74%	18	86%	
Abx							
Duration of abx (mean)	14.4		12.7		12.7		0.03
≤10 day course	0	0%	5	17%	8	43%	0.023

Results: abx duration





Results: Treatment failure at 1 month

	>10 day	course	≤10 day	Chi² p	
Patient number	43		13		value
Repeat/extended antibiotics	11	25%	0	0%	0.042
Admission	5	12%	1	8%	0.710
Death	0	0%	1*	8%	0.066
Death (anomaly removed)*	0		0		

^{*}Death at D6 of 14 prior to completion of abx

Results: Organisms grown

Organism grown	>10 day	/ course	≤10 day course		
Pseudomonas aeruginosa	20	47%	4	31%	
Pseudomonas aeruginosa and S. aureas	3	7%	0	0%	
Haemophilus influenzae	2	5%	2	15%	
Burkholderia cepacia	2	5%	0	0%	
Escherichia coli	1	2%	1	8%	
Mycobacterium chimera	1	2%	0	0%	
Stenotrophomonas maltophilia	2	5%	0	0%	
Achromobacter xylosoxidans	1	2%	1	8%	
Rhinovirus	1	2%	1	8%	
No growth	10	23%	1	8%	
Not available*	0	0%	3	23%	

Chi² p value = 0.052

^{*}pts who did not have sputum sent prior to starting abx

Results: Delays to start of OPAT

	Baseline		Cycle 1		Cycle 2		
Delays to start of OPAT	June - Sept		Oct - Dec		Jan - April		p value
Patients delayed	10	63%	8	42%	12	57%	0.281
Mean number of days (for those delayed)	3		5.7		4.2		0.705
Where delay reason identified:							
No H@H capacity	8	80%	3	38%	4	33%	
No PICC line	2	20%	4	50%	5	42%	
Regimens used							
OD	4	25%	9	47%	11	52%	
BD	2	13%	3	16%	3	14%	0.111
TDS	6	38%	4	21%	0	0%	0.111
Pump	4	25%	3	16%	7	33%	

QIP conclusions

- Simple interventions led to more pts being prescribed 10 days antibiotics as standard
- No obvious safety concerns identified (no increase in adverse events)
- Some evidence of reduced OPAT delays

What questions do you have?

<u>rachel.scott@nbt.nhs.uk</u> maria.miles6@nhs.net Possible reasons for patients not being prescribed 10 days:

- Clinician habit
- Patient expectations
- Minimal clinical improvement
- Microbial growth

Future ideas:

- Further reminders to consultants
 (and possibly teaching to residents)
- Patient information leaflet